NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » TOP 50 Pharmas  «  1  2  3  4  5  » 
found files: 188
Sanofi-Aventis »12/05/2008 [Company watch]
Sanofi-Aventis patent revoked in latest IP wrangle twist

The State Intellectual Property Office (SIPO) has invalidated the Chinese patent for France-based Sanofi-Aventis' anti-tumor drug, docetaxel, following a patent dispute with Jiangsu Hengrui Medicine Co. Ltd., the Chinese company announced last week. In September last year, Sanofi-Aventis filed a suit with the Beijing High Court alleging that Hengrui Medicine infringed its patent for docetaxel. The company is seeking a total of RMB 95.20 million ($14.36 million) in damages from Hengrui Medicine. Hengrui Medicine responded by applying to SIPO to revoke the company's patent. Liu Guiming, director of the SIPO's Patent Office declined to explain on what grounds the patent was withdrawn, "Because the case has not been finalized yet". "Sanofi-Aventis will probably appeal to the Beijing No. 1 Intermediate Court to get the patent reinstated, after which, the two companies will continue the infringement suit in the high court," Wang Bin, an intellectual property law consultant with the Shanghai Municipal Food and Drug Administration's Scientific and Technical Information Institute, told Interfax today. Sanofi-Aventis has three months to appeal the decision by SIPA. Yi Hui, a Sanofi-Aventis public relations official said today that the company is "now collecting the relevant documents [to appeal]." Dai Hongbin, board director of Hengrui Medicine, explained to Intefax Hengrui Medicine's position. "We started to market the drug in 2003. The patent application record shows that while Sanofi-Aventis first applied for a patent in 2001, the patent was not approved until 2006," he said. Dai said that Hengrui Medicine will not back down. "Hengrui Medicine has other new products which are set to become new growth points. Losing the case will not affect the company's financial performance overly, unless it is forced to pay a huge amount of compensation," Hao Jianjie, a pharmaceutical analyst with TX Investment Co. Ltd., said. "This will obviously be another lengthy patent tussle between a Chinese company and a foreign company in China," Wang said, noting the similarity to the ongoing battle by Pfizer over Viagra patent infringements in China. Hao concurred, explaining that it is not uncommon for a foreign company to pursue lengthy patent wars against Chinese companies, which do not usually have the financial means to put up an extended fight. Docetaxel, a cytotoxic injection mainly used in the treatment of breast, ovarian and non-small-cell lung cancer, makes up a key part of Hengrui Medicine's anti-tumor drug sales. By taking advantage of lower production costs in China, the company has been able to offer the drug at a lower price than Sanofi-Aventis....   more»

Roche »17/05/2008
Shanghai Roche Pharmaceutical to donate lung cancer drug to Chinese patients

Shanghai Roche Pharmaceutical announced in a May 15 press conference that it will donate supplies of Tarceva worth RMB 98 million to Chinese lung cancer patients unable to afford the drug. The drug will be given to patients in 21 cities across the country in October this year. According to clinical trial statistics by TRUST, Tarceva has a disease control rate of 79% in treating China patients with advanced non-small cell lung cancer. TRUST, the largest and longest ongoing study of Tarceva in lung cancer worldwide, involves nearly 12,000 NSCLC patients from 59 countries across Asia, the Middle East, Europe and the Americas...   more»

Schering-Plough »22/05/2008 [Company watch]
Shanghai Schering-Plough buys out JV Partner

Shanghai Schering-Plough is poised to follow Baxter Healthcare (Shanghai) and other multinationals in buying out local joint venture partners. This week, two domestic enterprises put their combined 45% stake of Shanghai Schering-Plough Pharmaceutical up for sale for RMB 66,329,550. Schering-Plough China, which owns 55%, is interested in purchasing the stake to achieve 100% ownership. In an interview a Schering-Plough spokesperson commented that the transaction is "going well", and if no other parties bid for the stake, the deal is expected to close by the end of June....   more»

Baxter International »30/05/2008 [Company watch]
Baxter, China and Toxic Heparin

Eighty-one deaths in the United States have been linked to allergic reactions to a Chinese-concocted contaminant in the widely used blood thinner heparin. The contaminant is an animal cartilage-derived oversulfated chondriotin sulfate. This ersatz non-FDA-approved chemical poorly mimics heparin but costs one one-hundredth of the price of legitimate heparin. Last month, FDA Commissioner Andrew Von Eschenbach told the US Senate that the replacement of heparin was not inadvertent, but an intentional act that was by “virtue of economic fraud.” This fraud joins several recent Chinese-initiated toxic chemical substitutions executed to save money for the Chinese suppliers while ultimately costing their American counterparts billions of dollars in litigation expenses and product recalls. The recalls included tainted pet food that killed hundreds of pets, after Chinese suppliers substituted melamine for wheat gluten; nephrotoxic melamine is cheaper than wheat gluten and is difficult to detect. Fake Colgate toothpaste was found contaminated with antifreeze that can cause kidney failure, convulsions, coma, or even death. There was excessive lead in paint on toys made in China that forced Mattel and other US toymakers to remove millions of toys from stores. In addition, there are over 350,000 web sites selling fake Chinese-manufactured Viagra and other fake US patented medicines to unsuspecting consumers who think they are purchasing the real thing. Where is the FDA in all these shenanigans? Apparently, nowhere. In the case of the toxic heparin, the FDA never even inspected the facility making the active pharmaceutical ingredient [API] for heparin. Since 75% of all API’s used by pharmaceutical companies are imported mainly from China and India, the FDA must have an effective yet timely response system to inspect proposed API facilities. Not only does this not exist, but also the FDA lacks funding to carry out its inspection duties. It is estimated that the FDA needs to spend $225 million on foreign plant inspections every other year. The FDA is budgeted $9 million. The time between plant inspections in the US is two years. In China, it is presently thirty years. This is because there are only 20 API facility visits per year to China for their 714 API facilities, which comes to a 30 years average time span between visits. In China, this does not include chemical manufacturers who may supply chemicals to the pharmaceutical industry. In this case, the Chinese FDA, the State Food and Drug Administration [SFDA] does not register the companies as API’s. Thus, they are exempt from Chinese SFDA regulations because they are classified as chemical manufacturers. And it was an exempt chemical manufacturer, Changzhou SPL Company Ltd., who supplied adulterated heparin to Baxter (BAX)-- the pharmaceutical company that supplies the vast majority of heparin used in the United States. When the FDA finally got around to inspect the manufacturing facility of Changzhou SPL, on a 5-day visit ending on February 26, 2008 there were numerous serious violations noted. The gist of FDA investigator Regina Brown’s report is summarized: There were no critical processing steps identified for Heparin Sodium. There were no documented steps identified for the removal of toxins such as heavy metals, bacteria, endotoxins and other impurities. There were no annual test results available. Basic written records such as set temperature and times as well as user observations during the manufacturing process was not recorded. When lots were tested and failed various tests such as the Nitrogen Determination Test, the investigations were recorded as being complete when in fact there was no determination recorded of why the sample failed the test in the first place. There was no impurity profile established for Heparin Sodium USP and no evaluation for degradants during stability program testing. An unacceptable (to the FDA) workshop vendor sold ingredients used in the manufacture of Heparin Sodium. The inside surface of large, "cleaned” tanks used in the final ?manufacturing? step, after both were very scratched, with unidentified material adhering to the insides and the tanks’ inverted handles held liquid, which spilled to the bottom of the tank when it was up righted. There was no written procedure showing that the tanks were dedicated to a particular process step. Raw material inventory records as well as waste records were incomplete. The shortcomings noted on the inspection report of Changzhou SPL Company Ltd. were so onerous, the FDA banned Chinese heparin imports into the United States. But this latest episode of the FDA not enforcing its own quality controls (until Americans die) belie the FDA’s ability to protect Americans from substandard manufactured drugs. If you buy any other product in the United States such as a car, toy or appliance, the country of origin must be displayed. Why is there no such disclosure for prescription drugs? Many prescription medicines that United States consumers buy are composed of active ingredients made in China. I wonder how many Americans would feel safe swallowing medicines coming from a country with the lowest quality control standards in the world....   more»

Pfizer »09/06/2008 [Company watch]
Pfizer to acquire Tianjin Tianyao Pharmaceutical

Chinese media reports that pharmaceutical giant Pfizer is negotiating with Tianjin Tianyao Pharmaceutical (SHA: 600488) for possible acquisition of the company. Tianjin Tianyao Pharmaceuticals is China's biggest manufacturer of Glucocorticoid APIs and second only to Pfizer in world production. Tianyao generated revenues of RMB 698.9 million in 2007, and reported net income of RMB 26 million, a decrease of 42% compared with the same period in 2006. The company is regarded as an industry leader in China. The Tianjin municipal government, which is trying to build a pharmaceutical park, has welcomed Pfizer into the city....   more»

Sanofi-Aventis »16/06/2008 [Company watch]
Sanofi Pasteur to donate 60 million doses of H5N1 Vaccine to WHO

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced its commitment to donate 60 million doses of H5N1 vaccine to the World Health Organization (WHO) over 3 years for the establishment of an H5N1 vaccine global stockpile. Mr Wayne Pisano, President and Chief Executive Officer of sanofi Pasteur, said, “The H5N1 virus is currently circulating in some of the poorest regions of the world and an outbreak of pandemic influenza would most likely hit populations living in areas with limited access to vaccines. This donation of H5N1 vaccine aims to address the needs of those most vulnerable populations." "In addition to supporting the efforts of governments, it is essential that industry collaborates with international organizations such as WHO, the Bill and Melinda Gates Foundation and other global health players. This is the best way to build a stockpile of vaccines for developing nations, ready to be deployed on the ground in the event of a pandemic flu outbreak," added Mr Pisano. Each year since 2004, sanofi pasteur produced millions of doses of H5N1 avian influenza vaccine, both in France and in the United States. In April 2007, the US Food and Drug Administration (FDA) licensed sanofi pasteur's H5N1 vaccine, the first avian influenza vaccine for humans in the US. Sanofi Pasteur recently conducted clinical trials with a novel, proprietary adjuvant aimed at dramatically reducing the amount of antigen needed to elicit a protective immune response to the H5N1 strain currently identified by global health authorities and experts as a potential source for the next pandemic. These data show the ability of this new investigational H5N1 pandemic influenza vaccine to generate a high immune response with a very low dose of H5N1 antigen. Sanofi Pasteur is committed to producing as many doses as possible of its most advanced vaccine in the shortest possible timeframe should a pandemic be declared by WHO. Under such circumstances, sanofi pasteur's seasonal influenza vaccine facilities would globally be able to switch to pandemic vaccine manufacturing. Sanofi Pasteur recently completed the construction of a new influenza vaccine manufacturing facility in the United States. This new facility is planned to go online in 2009. Sanofi Pasteur is also on track to build a facility to manufacture seasonal influenza vaccine in China for the local market. This vaccine manufacturing facility is due to be operational by 2012. A new formulation and filling facility located in France is also planned to become operational in 2009. This new state-of-the-industry facility will boost sanofi pasteur's filling capabilities. With the production of 180-million doses of seasonal influenza vaccine last year, sanofi pasteur confirmed its leadership by supplying an estimated 40 percent of the world influenza vaccine marke...   more»

Pfizer »13/06/2008
Novamed selected as Pfizer/Baxter China Strategic Partner

NovaMed Pharmaceuticals Inc, a leading China-based pharmaceutical company which provides outsourced drug development and commercialization services for global multinational pharmaceutical and biotechnology companies and Pfizer China today announced an exclusive strategic partnership in the oncology area. The agreement indicates that NovaMed will serve as Pfizer China’s sole distributional and promotional partner for six of its oncology products throughout mainland China starting June, 2008. It is the first alliance of its kind for Pfizer China’s oncology portfolio. The partnership creates a window of opportunity in China’s health care environment in which multinationals can strategically outsource established drugs to companies with wide and well-established distribution networks across the country. With cancer ranked the leading cause of mortality in China, an annual increase of 1.6-1.7 million cancer patients is expected in addition to the approximately 4.5 million existing oncology patients. The unique outsourcing model significantly increases the number of patients benefiting from clinically proven and effective therapies. NovaMed expects a 30-40% increase in hospital coverage of these six Pfizer China oncology drugs across China. NovaMed has continued to strengthen its position in China’s oncology market since its first oncology deal with Baxter China for three of its long-standing oncology products. With a total market value of RMB 40 billion, the oncology therapeutic area is the second largest in China, after the antibiotic market. Its current oncology portfolio offers a wide range of therapies across key disease areas including medical oncology, hematology and urology. NovaMed will also continue to pursue the licensing of oncology products from international companies– these include both products that have been launched in international markets (but are not yet available in China) and products which are currently still in the development cycle. Mark Lotter, CEO and co-founder of NovaMed, commented, “NovaMed is committed to partnering with global pharmaceutical companies to help international drug brands achieve their full potential in an emerging market such as China and to allow a wider population of patients in China to gain access to best-in-class drugs. NovaMed has established a solid foundation for building an oncology portfolio which positions the company well in terms of its immediate, medium and long term presence in the oncology market in China.” Oncology is a rapidly growing therapeutic area internationally with the sales of cancer drugs expected to double at the rate of the global pharmaceutical market and reach USD 80 billion by 2012 according to a recent IMS report. “Pfizer China is delighted to have the opportunity to partner with NovaMed. NovaMed’s oncology team excels in terms of its abundant distribution and marketing experience and expertise, as well as its solid relationships with key oncology centers and thought leaders across the nation. All of these factors will greatly aid the promotion of oncology products, help bring more treatment options to the market and ultimately benefit a larger proportion of oncology patients,” said Xiaoyu Sun, Associate Director of the Commercial and Retail Business Department at Pfizer China. According to Thomas Zan, Director of Critical Care Business Unit at Baxter China, “NovaMed’s in-depth knowledge and understanding of China’s oncology environment is the key to its success. We have been very impressed with NovaMed’s strong and dedicated management team and the uniquely sustainable business model it offers to China’s oncology market. Since signing the deal for three of our oncology products in September 2007, NovaMed has demonstrated its solid execution capability through building extensive alliances with oncology distributors and partners across the country and facilitating hospital listing, tendering and pricing.” NovaMed’s exclusive distributional and promotional agreement with Pfizer China allows access to six of Pfizer's oncology products within China: Adriamycin, Daunoblastina, Leucovorin, Methotrexate, Estracyt and Farlutal. The three oncology products from Baxter China are Holoxan, Mesna and Endoxan. These key partnerships have effectively catapulted NovaMed into becoming a highly competitive force in China’s oncology market. Together with its leading commercial team, it continues to be an attractive target as a partner for global companies who wish to maximize their presence in China....   more»

Bayer »24/06/2008 [Company watch]
Will Bayer AG Overtake AstraZeneca in China Drug Sales

According to Reuters, Germany's Bayer AG (BYERF.PK) thinks it can become the biggest seller of prescription drugs in China this year, bypassing AstraZeneca (NYSE: AZN), which is currently the top dog. Arthur J. Higgins, the head of Bayer Healthcare, said that revenues in China are growing at more than 40% annually. In 2008, they will top $500 million for the Germany-based pharma giant. Worldwide, Higgins expects Bayer will do some small deals this year, probably in medical devices, diabetes care, animal health and regional opportunities in over-the-counter medicines, but would most likely not undertake a mega-transaction, even though it has the capacity to do so. He also said that Bayer would not make a major purchase of a generic firm. It is currently doing quite well with its off-patent drugs in China, so a generic acquisition would not be helpful...   more»

Pfizer »24/06/2008 [Company watch]
NovaMed to distribute six oncology products for Pfizer China

NovaMed Pharmaceuticals announced June 13 that is has entered into an agreement with Pfizer China under which it will act as the exclusive distributor and promoter for six of Pfizer China's anticancer products. NovaMed expects hospital coverage of the products, Adriamycin, Daunoblastina, Leucovorin, Methotrexate, Estracyt and Farlutal, to increase by 30% to 40% in China. NovaMed is a specialty pharmaceutical company providing commercialization and outsourcing services in China for global pharmaceutical and biotech companies. The company seeks to license products that have been launched in international markets but are not yet available in China as well as development stage products. NovaMed has successfully in-licensed programs from several multinational pharmaceutical companies, including recent agreements with Sanofi-Aventis, Baxter International, and Meda AB....   more»

Pfizer »01/07/2008 [Company watch]
Pfizer Cuts Costs by Outsourcing Drug Distribution in China

NovaMed will sell and promote six anti-tumor drugs in China for Pfizer China, a subsidiary of big pharma company Pfizer Inc. (NYSE: PFE). The contract began in June 2008. Pfizer China projects that the out-sourcing will increase its coverage ratio in China hospitals for the products by 30% to 40%. NovaMed will be responsible for distribution and promotion of Pfizer China's adriamycin, dauniblastina, leucoyorin, methotrexate, estracyt, and farkutal. The marketing out-sourcing contract is a first for Pfizer China. Worldwide, its Pfizer parent company is determined to cut costs by increasing its use of out-sourcing, though this was expected to occur mainly in the manufacturing sector. Pfizer will close or sell 45 pharmaceutical factories, and to increase its total outsourcing from 10% currently to 30% in two years....   more»

Novartis »25/06/2008 [Company watch]
SFDA approves Novartis flu vaccine for elderly

The State Food and Drug Administration (SFDA) announced June 25 that it has approved the first influenza vaccine for the elderly in China. The vaccine, Fluad®, is an MF59-adjuvanted vaccine made by Novartis. According to the World Health Organization (WHO), many influenza strains originate in China; however, less than 5% of the elderly in China receive immunization. In some developed countries, nearly 60% of the elderly population receives influenza vaccinations....   more»

Schering-Plough »30/06/2008 [Company watch]
Schering-Plough China buys back Shanghai Schering

According to the Shanghai United Assets and Equity Exchange, 45% equity of Shanghai Schering-Plough Ltd. held by Shanghai Pharmaceutical Group and Shanghai Pharmaceutical Industry Corporation has been sold to Schering-Plough China for RMB 66.3 million, a move that will make Shanghai Schering-Plough a wholly foreign-owned enterprise once the transaction is finalized in July. Shanghai Schering-Plough Pharmaceutical, a joint venture, has a registered capital of USD 21 million. Prior to the sale, 30% of the firm was held by Shanghai Pharmaceutical Industry Corporation, 15% by Shanghai Pharmaceutical (Group), and the remaining 55% by Schering-Plough China. There remains some controversy surrounding the share sale; local media claim the New-Jersey based MNC has pursued a 'loss strategy' to drive out its Chinese partners. A spokesperson from Shanghai Pharmaceutical (Group), however, denied the claims, stating that the share sale is due to the Group's unwillingness to guarantee new loans to the company....   more»

Johnson & Johnson »11/07/2008 [Company watch]
J&J sets up diabetes institute in Beijing

J&J sets up diabetes institute in Beijing Johnson & Johnson has established a diabetes institute as of July 11 in Beijing, the fourth non-profit institute financed by the company worldwide. The new institute will focus on providing training for Chinese diabetes professionals and developing a disease management model for diabetes. China had 39.8 million diabetes patients in 2007, second only to India....   more»

GlaxoSmithKline »11/07/2008 [Company watch]
GlaxoSmithKline to Double China R&D Staff

GlaxoSmithKline Plc announced that it will increase its China-based research and development staff to 350 people in the next few years. Currently, the company has 170 employees on its R&D roster at its Shanghai facility. That number will move up to 200 by the end of this year, and it will jump to 350 within a year or so. At that point, staffing will level off for three or four years while new facilities are built. The comments were made at the ChinaBio Investor Forum held in Shanghai by Carol Zhu, who is head of operation management and alliances in the R&D department for GSK. The ChinaBio Investor Forum was organized by the ChinaBio Accelerator, which is a sister organization to ChinaBio Today.These increases are lower than the numbers projected at the end of 2007. In December 2007, GSK said it expected to have invested $100 million in its Shanghai facility by the end of 2008 and have 1000 staff members employed there by 2010. When it was started, GSK’ Shanghai R&D center had the stated goal of focusing on neurodegenerative diseases such as multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease. The Shanghai center was tasked with eventually directing GSK’s R&D activities in this therapeutic area, coordinating with other GSK centers around the world and research institutions in China and globally. The Shanghai center began operations in the summer of 2007....   more»

Sanofi-Aventis »29/07/2008 [Company watch]
Sanofi Anentis Extends Collaboration in China

NovaMed Pharmaceuticals Inc, a leading China-based pharmaceutical company which provides outsourced drug development and commercialization services for global multinational pharmaceutical and biotechnology companies today announced that their collaboration with sanofi-aventis in China has been extended, beginning July 2008. In addition to the exclusive outsourcing of five other established sanofi-aventis China drugs in China, NovaMed is now also charged with the promotion and distribution of Depakine®, the treatment of choice for epilepsy worldwide since the 1970s. Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China, marks the sixth sanofi-aventis product for NovaMed to commercialize in China. The world leading pharmaceutical company, No. 1 in Europe, sanofi-aventis was the first to partner with NovaMed in China after its foundation in 2006, for the outsourcing of a series of central nervous system (CNS), cardiovascular and urology products. The ongoing collaborative relationship between the two companies began in 2006 with Xatral®, the first product in a class of alpha1-blockers to treat benign prostatic hyperplasia (BPH). A recent IMS Health report revealed that Xatral® has demonstrated very strong growth, notably at the highest rate in the BPH treatment market since the cooperation with NovaMed began. The focus on collaboration with multinational pharmaceutical companies in China underscores the opportunity for NovaMed to expand hospital coverage in various cities across China and facilitate greater patient access to clinically proven and effective therapies. NovaMed is now the exclusive promotion partner of three sanofi-aventis CNS products in China, including Depakine®, Stilnox® and Perenan®. In addition, it is sanofi-aventis China’s appointed outsourcing partner for Tritace® (cardiovascular), Xatral®(urology), and Rulide® (Infection). Tritace® is one of the leading treatment options for hypertension and high risk cardiovascular patients in the market and Stilnox® is the most widely prescribed hypnotic in the US for improving the continuity and quality of sleep. The collaboration with sanofi-aventis with Depakine allows NovaMed to continue to strengthen its sales and marketing efforts in the CNS pipeline. The company’s sales and marketing team is currently over 350 people strong across China and includes a special oncology business unit of 55 people....   more»

GlaxoSmithKline »24/07/2008 [Company watch]
GlaxoGSK Makes Generics Deal to Penetrate Emerging Markets

SmithKline has made a strategic alliance with Aspen PharmaCare, a South African generic drug company, as a means of penetrating emerging markets such as China. GSK noted that 40% of the expected growth in pharmaceutical markets worldwide will be in emerging countries. GSK did not pay an upfront fee in its arrangement with Aspen, but will make a small upfront payment for each product that it elects to register and then pay royalties, as the big pharma extends the marketing range of Aspen’s products into new territories....   more»

GlaxoSmithKline »23/07/2008 [Company watch]
GSK sets out new strategic priorities

In a presentation to investors today, Andrew Witty, CEO GlaxoSmithKline, set out three new strategic priorities that aim to increase growth, reduce risk and improve GSK’s long-term financial performance. Outlining the context for the priorities Witty said: “In the next few years the pharmaceutical industry will face immense challenges as an unprecedented number of products lose patent protection. This will be set against a backdrop of payors searching for ever more cost-effective healthcare and escalating patient demand for new and better medicines.” “Our aspiration to improve the lives of patients and consumers is intrinsically aligned to the requirements of our shareholders,” he said. At the same time though, he stated that the industry is currently perceived in financial terms as being one of ‘higher risk’ and ‘lower growth’ and that companies must work harder to demonstrate greater return from investments in R&D. “These new strategic priorities will evolve GSK into a company that has a balanced group of healthcare businesses and a lower overall risk profile,” said Witty. “They also point to a more disciplined allocation of capital across all our different business areas...   more»

Bayer »29/07/2008 [Company watch]
China approves Nexavar to treat liver cancer

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, have said that the State Food and Drug Administration (SFDA) of China has approved Nexavar (sorafenib) tablets for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC), or liver cancer. Nexavar is the first and only oral targeted therapy to significantly improve overall survival in patients with the disease. The approval was based on two international phase III double blind, placebo-controlled trials that evaluated more than 800 patients who received no prior systemic therapy. Dr Gunnar Riemann, member of the executive committee of Bayer HealthCare, said China has the highest number of liver cancer patients worldwide with more than 340,000 new cases diagnosed each year and the incidence is continuing to rise. We are proud to be at the forefront of liver cancer treatment with Nexavar and are hopeful that patients in China can potentially have their lives extended by treatment with Nexavar. “The approval in liver cancer in China comes less than two years after the approval in advanced kidney cancer and proves that Nexavar is and will continue to be an important foundational therapy in multiple patient populations,” said Dr N Anthony Coles, president and chief executive officer, Onyx Pharmaceuticals. Hepatocellular carcinoma is the most common form of liver cancer and is responsible for about 90 percent of the primary malignant liver tumors in adults. Liver cancer is the sixth most common cancer in the world and the third leading cause of cancer-related deaths globally. In the Asia-Pacific region, more than eight percent of the general population is infected with chronic hepatitis B and between two and four percent is infected with chronic hepatitis C. Both infections are the leading causes of primary liver cancer worldwide...   more»

Merck & Co »28/07/2008 [Company watch]
Huahai Pharmaceutical to Produce Patent Drug for Merck

Both sides have inked an agreement. Huahai Pharmaceutical will be responsible for production of a patent drug for Merck, covering formulation, production and packaging of the drug, and the US firm will exclusively sell the products in the international market....   more»

Eli Lilly & Co »07/08/2008 [Company watch]
China makes small contribution to Lilly's profit growth

While global profit for Eli Lilly & Co. (NYSE:LLY) rose 31% to USD 958 million in the second fiscal quarter of 2008, the sales revenue from Lilly China comprised a relatively insignificant portion of global sales, according to Ming Cao, director of sales for Lilly China. China sales of Eli-Lilly's anti-impotence drug Cialis, for example, accounted for less than 1% of its 2007 global USD 1.2 billion revenue, and the firm does not expect the drug to become profitable in the country in the next five or six years. Cao added that although Lilly's China market is relatively small, it is growing at a robust 30% annually....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.